OLMESARTAN

Olmesartan is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension and heart failure. It received FDA approval in 2002. Clinical trials have demonstrated efficacy in reducing blood pressure by blocking angiotensin II, a hormone responsible for vasoconstriction. Approval was supported by studies establishing its safety, efficacy, and tolerability. Olmesartan is characterised by a prolonged half-life, which permits once-daily dosing and maintains consistent blood pressure control over 24 hours. Clinical trials have shown that Olmesartan reduces the incidence of stroke, myocardial infarction, and renal complications in patients with hypertension.

Olmesartan is primarily used to treat: Hypertension : It is effective in lowering high blood pressure in both adults and children over the age of 6. Heart failure : It may be used in combination with other medications to manage symptoms of heart failure and reduce the risk of hospitalisations. Chronic kidney disease : In patients with kidney disease, particularly those with diabetes, Olmesartan may be prescribed to help protect kidney function by reducing proteinuria (excess protein in the urine).

Olmesartan is available in tablet form, with common dosages of 20, 40, and 80mg. The typical initial dose for adults is 20 mg once daily, with the option to increase to 40 mg once daily if necessary. The dosage may be adjusted depending on the individual’s response, and for patients with renal or hepatic impairment, lower doses may be required. It is important to take Olmesartan at the same time each day, preferably with or without food, to maintain consistent blood pressure control.

Common side effects of Olmesartan include: Dizziness or lightheadedness, especially when standing up Fatigue Headache Back pain Diarrhea Serious but rare side effects may include: Angioedema (swelling) Severe hypotension (very low blood pressure) Elevated potassium levels (hyperkalemia) Kidney problems (elevated serum creatinine levels)

Pregnancy : Olmesartan is contraindicated during pregnancy, particularly during the second and third trimesters, as it can harm the developing fetus. Renal Impairment : Extra caution is recommended for patients with severe kidney impairment, as Olmesartan may affect kidney function. Electrolyte Imbalance : Olmesartan can cause imbalances in potassium, sodium, and creatinine levels. Regular monitoring of these electrolytes is recommended during treatment. Angioedema : Rarely, Olmesartan may cause angioedema (swelling of deeper layers of skin, often around the eyes and lips). If this happens, seek medical attention without delay.

Hypotension : Patients who are volume-depleted, such as those on diuretics, may experience excessive drops in blood pressure. It is advisable to correct any dehydration before starting Olmesartan. Liver Disease : Caution is recommended in patients with liver impairment, as Olmesartan is metabolised in the liver. Interaction with Other Medications : Olmesartan may interact with other antihypertensive drugs, potassium supplements, or potassium-sparing diuretics. Therefore, inform your healthcare provider of all medications you are taking.

Take Olmesartan at the same time each day to maintain consistent blood pressure control. Monitor your blood pressure regularly to ensure it stays within your target range. Avoid consuming grapes or grapefruit juice, as these may interact with the medication. In addition to Olmesartan therapy, a balanced diet, regular physical activity, and stress reduction techniques can support improved blood pressure management. Inform your doctor before commencing any new medications, including over-the-counter preparations, supplements, or potassium-based products.

https://www.ncbi.nlm.nih.gov/books/NBK544367/ https://www.drugs.com/mtm/olmesartan.html https://www.nhs.uk/medicines/olmesartan/